Dr. James De Lemos, MD

Cardiovascular Disease Dallas, TX Male
NPI: 1972566602
Total Payments
$448,409
2024 Payments
$57,283
Companies
20
Transactions
167
Medicare Patients
2,874
Medicare Billing
$95,684

Payment Breakdown by Category

Research$243,195 (54.2%)
Consulting$189,009 (42.2%)
Other$7,750 (1.7%)
Travel$6,819 (1.5%)
Food & Beverage$1,637 (0.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $243,195 50 54.2%
Consulting Fee $189,009 65 42.2%
Travel and Lodging $6,819 22 1.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,000 1 0.9%
Honoraria $3,750 2 0.8%
Food and Beverage $1,637 27 0.4%

Payments by Type

Research
$243,195
50 transactions
General
$205,214
117 transactions

Top Paying Companies

Company Total Records Latest Year
Ortho-Clinical Diagnostics, Inc. $139,374 16 $0 (2020)
Novo Nordisk AS $90,206 21 $0 (2024)
Amgen Inc. $38,490 22 $0 (2024)
Radiometer America, Inc $28,650 3 $0 (2017)
Siemens Medical Solutions USA, Inc. $23,700 10 $0 (2024)
Regeneron Pharmaceuticals, Inc. $21,488 10 $0 (2023)
Eli Lilly and Company $21,487 18 $0 (2023)
Janssen Research & Development, LLC $18,063 9 $0 (2024)
Quidel Corporation $16,684 8 $0 (2022)
Merck Sharp & Dohme LLC $9,865 19 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $57,283 36 Novo Nordisk AS ($18,906)
2023 $41,406 15 Novo Nordisk AS ($14,725)
2022 $61,128 31 Eli Lilly and Company ($18,687)
2021 $26,919 9 Novo Nordisk AS ($21,375)
2020 $66,686 20 Ortho-Clinical Diagnostics, Inc. ($34,800)
2019 $96,783 18 Ortho-Clinical Diagnostics, Inc. ($72,100)
2018 $30,721 21 Ortho-Clinical Diagnostics, Inc. ($12,000)
2017 $67,484 17 Radiometer America, Inc ($28,650)

All Payment Transactions

167 individual payment records from CMS Open Payments — Page 1 of 7

Date Company Product Nature Form Amount Type
12/11/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $370.60 General
Category: CARDIOVASCULAR
12/11/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
12/11/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
12/10/2024 Siemens Medical Solutions USA, Inc. — Consulting Fee Cash or cash equivalent $1,050.00 General
12/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $370.60 General
Category: CARDIOVASCULAR
12/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
12/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
10/21/2024 Novo Nordisk AS Rybelsus (Drug) — Cash or cash equivalent $9,106.25 Research
Study: EX9924-4473 • Category: Diabetes
10/21/2024 Novo Nordisk AS Rybelsus (Drug) — In-kind items and services $5,920.70 Research
Study: EX9924-4473 • Category: Diabetes
10/21/2024 Novo Nordisk AS Rybelsus (Drug) — In-kind items and services $543.51 Research
Study: EX9924-4473 • Category: Diabetes
10/21/2024 Novo Nordisk AS Rybelsus (Drug) — In-kind items and services $318.20 Research
Study: EX9924-4473 • Category: Diabetes
10/21/2024 Novo Nordisk AS Rybelsus (Drug) — In-kind items and services $111.19 Research
Study: EX9924-4473 • Category: Diabetes
10/01/2024 Amgen Inc. — Consulting Fee Cash or cash equivalent $2,200.00 General
09/17/2024 Janssen Research & Development, LLC — Consulting Fee Cash or cash equivalent $4,550.00 General
09/17/2024 Janssen Research & Development, LLC — Travel and Lodging Cash or cash equivalent $219.44 General
09/16/2024 AstraZeneca Pharmaceuticals LP — Consulting Fee Cash or cash equivalent $1,000.00 General
09/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $852.38 General
Category: CARDIOVASCULAR
09/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $827.31 General
Category: CARDIOVASCULAR
09/09/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $827.31 General
Category: CARDIOVASCULAR
09/03/2024 Siemens Medical Solutions USA, Inc. — Consulting Fee Cash or cash equivalent $5,100.00 General
08/29/2024 Janssen Research & Development, LLC — Travel and Lodging In-kind items and services $521.00 General
08/29/2024 Janssen Research & Development, LLC — Food and Beverage In-kind items and services $50.00 General
08/05/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $370.60 General
Category: CARDIOVASCULAR
08/05/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
08/05/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $359.70 General
Category: CARDIOVASCULAR
123…7»

Research Studies & Clinical Trials

Study Name Company Amount Records
EX9924-4473 Novo Nordisk AS $79,006 18
NT-proBNP Ortho-Clinical Diagnostics, Inc. $74,737 6
Troponin Ortho-Clinical Diagnostics, Inc. $54,400 8
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUSFAMILIAL HYPERCHOLESTEROLEMIA Regeneron Pharmaceuticals, Inc. $16,538 7
GOULD Amgen Inc. $13,174 4
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA Regeneron Pharmaceuticals, Inc. $4,950 3
Primary 2-Year Results of GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Diseas Amgen Inc. $157.77 1
ACUTE ISCHEMIC STROKE IN THE CORONAVIRUS DISEASE 2019 ERA AN ANALYSIS FROM GET WITH THE GUIDELINES-STROKE F. Hoffmann-La Roche AG $87.91 1
(GOULD): a Registry of High Cardiovascular Risk Subjects in the United States Amgen Inc. $73.33 1
Use of guideline-recommended risk-reduction strategies among patients with Type 2 diabetes and estab Amgen Inc. $71.50 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 139 196 $60,274 $15,849
2022 8 734 985 $106,792 $22,706
2021 9 993 1,325 $127,071 $27,428
2020 10 1,008 1,360 $137,727 $29,700
Total Patients
2,874
Total Services
3,866
Medicare Billing
$95,684
Procedure Codes
34

All Medicare Procedures & Services

34 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 62 67 $23,048 $6,231 27.0%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 12 46 $15,456 $4,372 28.3%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 20 28 $12,992 $3,546 27.3%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 11 11 $7,194 $1,423 19.8%
93010 Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only Facility 2023 34 44 $1,584 $277.42 17.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 74 85 $29,240 $7,400 25.3%
93010 Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only Facility 2022 495 710 $25,560 $4,511 17.6%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 23 29 $13,456 $3,889 28.9%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 24 40 $13,440 $2,952 22.0%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 13 13 $8,502 $1,914 22.5%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 13 16 $3,744 $874.26 23.4%
99238 Hospital discharge day management, 30 minutes or less Facility 2022 11 11 $2,563 $628.04 24.5%
93000 Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report Office 2022 81 81 $10,287 $537.70 5.2%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 67 78 $26,832 $7,487 27.9%
93010 Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report Facility 2021 700 981 $35,316 $6,376 18.1%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 23 33 $15,312 $4,381 28.6%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 13 27 $9,072 $2,254 24.8%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 13 13 $8,502 $2,084 24.5%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 17 33 $7,722 $1,899 24.6%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 12 12 $5,340 $1,358 25.4%
99238 Hospital discharge day management, 30 minutes or less Facility 2021 18 18 $4,194 $1,044 24.9%
93000 Routine ekg using at least 12 leads including interpretation and report Office 2021 111 111 $14,097 $490.57 3.5%
93010 Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report Office 2021 19 19 $684.00 $53.84 7.9%
93010 Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report Facility 2020 716 1,004 $36,144 $6,651 18.4%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 63 80 $27,520 $6,531 23.7%
12»

About Dr. James De Lemos, MD

Dr. James De Lemos, MD is a Cardiovascular Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972566602.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James De Lemos, MD has received a total of $448,409 in payments from pharmaceutical and medical device companies, with $57,283 received in 2024. These payments were reported across 167 transactions from 20 companies. The most common payment nature is "" ($243,195).

As a Medicare-enrolled provider, De Lemos has provided services to 2,874 Medicare beneficiaries, totaling 3,866 services with total Medicare billing of $95,684. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.

Practice Information

  • Specialty Cardiovascular Disease
  • Location Dallas, TX
  • Active Since 04/12/2006
  • Last Updated 01/29/2008
  • Taxonomy Code 207RC0000X
  • Entity Type Individual
  • NPI Number 1972566602

Products in Payments

  • Clinical Chemistry (Device) $118,900
  • Rybelsus (Drug) $47,131
  • RYBELSUS (Drug) $31,875
  • AQT90 (Device) $28,650
  • Repatha (Biological) $27,677
  • XARELTO (Drug) $11,981
  • Transfusion Medicine (Device) $10,237
  • EVKEEZA (Biological) $8,550
  • CD cobas Reagents (Device) $4,798
  • Ozempic (Drug) $2,800
  • Tresiba (Drug) $2,400
  • Corlanor (Drug) $2,380
  • Architect Troponin-I (High Sensitive) (Device) $146.73
  • Victoza (Drug) $118.34
  • RESOLUTE ONYX (Device) $116.16
  • Activase (Biological) $87.91

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Cardiovascular Disease Doctors in Dallas

Darren Mcguire, Md, MD

Cardiovascular Disease — Payments: $2.0M

Cardiovascular Disease $2.0M

Dr. Peter Mccullough, Md, Mph, MD, MPH

Cardiovascular Disease — Payments: $1.3M

Cardiovascular Disease $1.3M

Robert Stoler, M.d, M.D

Cardiovascular Disease — Payments: $719,078

Cardiovascular Disease $719,078

Dr. Ann Navar, Md, Phd, MD, PHD

Cardiovascular Disease — Payments: $672,005

Cardiovascular Disease $672,005

Martin Berk, M.d, M.D

Cardiovascular Disease — Payments: $493,450

Cardiovascular Disease $493,450

Eric Peterson, M.d, M.D

Cardiovascular Disease — Payments: $404,014

Cardiovascular Disease $404,014